4. CONCLUSION
Here, we reported the first case of piperacillin-tazobactam-induced
immune thrombocytopenia successfully challenged by the use of meropenem
and cefotiam, but cannot tolerant with cefoperazone-sulbactam for the
treatment of pneumonia. Although the
exact responsible antibodies of piperacillin-tazobactam-induced immune
thrombocytopenia remain unknown and need further investigation,
attention should be paid to the role of chemical structure similarities
in determining the risk of DITP among beta-lactams in the clinical
setting.